A44.1
Cutaneous and mucocutaneous bartonellosis
Clinical Classification Guidelines
Inclusion Terms
- Verruga peruana
Medical Intelligence & Overview
Cutaneous and mucocutaneous bartonellosis, also known as Verruga peruana, is a bacterial infection caused by certain species of the Bartonella genus. This condition primarily affects the skin and mucous membranes, leading to characteristic skin lesions. Although it is more common in certain regions, especially in South America, understanding its presentation and implications can help in early recognition and management.
Causes & Symptoms
Clinical Causes: Infection with Bartonella bacteria, typically transmitted through insect vectors such as sandflies or lice. Exposure to endemic areas where the bacteria are prevalent, including parts of South America like Peru, Bolivia, and Ecuador. Potential transmission through blood transfusions or contact with infected animals in some cases.
Key Symptoms: Development of vascular skin lesions known as verrucous or nodular growths, which can be soft or firm. Lesions typically appear on the skin or mucous membranes, including lips, nose, or genital areas. Lesions may be painless but can become ulcerated or bleed in advanced stages. In some cases, patients may experience mild fever, malaise, or weight loss, especially if the infection is widespread. Swelling of nearby lymph nodes may be observed. In chronic cases, skin lesions can persist for months or years if untreated.
Diagnostic & Treatment
Diagnosis Path: Diagnosis is generally based on the clinical appearance of skin lesions, location, and patient's history, including travel to endemic regions. Laboratory tests such as skin biopsies, histopathological examination, or microbiological cultures may confirm the presence of Bartonella bacteria. Serological testing and molecular methods like PCR (polymerase chain reaction) are also utilized to identify the specific pathogen.
Treatment Protocols: Management often involves antibiotic therapy tailored to the severity and location of lesions. Common antibiotics may include doxycycline, azithromycin, or rifampin. In some cases, surgical removal or cryotherapy of lesions may be necessary. Supportive care and monitoring are important to prevent secondary infections or complications. Early intervention can improve outcomes and reduce the risk of chronicity.
Clinical Advice & FAQs
Billing Guidance
Is A44.1 a billable ICD-10 code?
Yes, A44.1 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report A44.1?
Clinical documentation must specify the nature of Cutaneous and mucocutaneous bartonellosis and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
